AAD 2022: Baricitinib Superior to Placebo for Hair Regrowth in Alopecia Areata
In two phase 3 studies, greater percentage of patients randomly assigned to baricitinib versus placebo achieved SALT score of 20 or less at week 36
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.